Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 80

Results For "event"

1895 News Found

Boehringer Ingelheim introduces NexGard Spectra for dogs in India
News | April 22, 2024

Boehringer Ingelheim introduces NexGard Spectra for dogs in India

NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs


PharmaLytica 2024 to draw 200+ exhibitors
News | April 19, 2024

PharmaLytica 2024 to draw 200+ exhibitors

10th edition of the event is scheduled to be held during May 30-June 1 at Hitex, Hyderabad


USFDA grants ODD to NM5072 for treatment of Paroxysmal Nocturnal Hemoglobinuria
News | April 17, 2024

USFDA grants ODD to NM5072 for treatment of Paroxysmal Nocturnal Hemoglobinuria

NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections


Syntegon showcases oral solid dosage portfolio at Achema
News | April 11, 2024

Syntegon showcases oral solid dosage portfolio at Achema

Fluid bed processes: drying, granulating, and coating in just one product container


President Murmu to inaugurate homeopathic symposium on World Homoeopathy Day 2024
News | April 10, 2024

President Murmu to inaugurate homeopathic symposium on World Homoeopathy Day 2024

Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium


Bayer and Dr. Reddy's sign marketing and distribution agreement for second brand of Vericiguat in India
News | April 07, 2024

Bayer and Dr. Reddy's sign marketing and distribution agreement for second brand of Vericiguat in India

Vericiguat works on a pathway not currently targeted by existing heart failure treatments


Dr Reddy's partners with Sanofi India to distribute vaccine brands in India
News | March 28, 2024

Dr Reddy's partners with Sanofi India to distribute vaccine brands in India

Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U


Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder
Drug Approval | March 27, 2024

Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder

First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+


FDA approves Merck’s WINREVAIR for treatment of pulmonary arterial hypertension
Drug Approval | March 27, 2024

FDA approves Merck’s WINREVAIR for treatment of pulmonary arterial hypertension

WINREVAIR is a breakthrough biologic for this rare, progressive disease